For several years, our group has been developing quinoxalinic compounds. Two of them, N-methyl-1-(2-phenethyl)imidazo[1,2-a]quinoxalin-4-amine (EAPB0203) and 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0503), have emerged as the most promising anticancer drugs. In the present work, we determined metabolism pathways using liver microsomes from four mammalian species including human. We identified the cytochrome P450 isoform(s) involved in the metabolism and then investigated the pharmacokinetics and metabolism of EAPB0203 and EAPB0503 in rat after intravenous and intraperitoneal administration. Biotransformation of the compounds involved demethylation and hydroxylation reactions. Rat and dog metabolized the compounds at a higher rate than mouse and human. In all species, CYP1A1/2 and CYP3A isoforms were the predominant enzymes responsible for the metabolism. From human liver microsomes, unbound intrinsic clearances were approximately 56 ml/(min ⅐ g) protein. EAPB0203 and EAPB0503 were extensively bound to human plasma proteins, mainly human serum albumin (HSA) (ϳ98-99.5%). Thus, HSA could act as carrier of these compounds in human plasma. Scatchard plots showed patterns in which the plots yielded upwardly convex hyperbolic curves. On the basis of the Hill coefficients, there appears to be interaction between the binding sites of HSA, suggesting positive cooperativity. The main in vitro metabolites were identified in vivo. Total clearances of EAPB0203 and EAPB0503 [3.2 and 2.2 l/(h ⅐ kg), respectively] were notably lower than the typical cardiac plasma output in rat. The large volumes of distribution of these compounds (4.3 l/kg for EAPB0203 and 2.5 l/kg for EAPB0503) were consistent with extensive tissue binding. After intraperitoneal administration, bioavailability was 22.7% for EAPB0203 and 35% for EAPB0503 and a significant hepatic first-pass effect occurred.
Introduction
Melanoma and T-lymphoma are major public health problems; their incidence and mortality rates are increasing in the world population and, despite a major effort in clinical research to scrutinize various treatment regimens, the prognosis for patients still remains poor. Given the limited effectiveness of a large variety of conventional anticancer drugs, novel approaches or drugs are urgently needed.
For several years, our group has been developing quinoxalinic compounds. Three chemical series have been synthesized: the imidazo[1,2-a]quinoxalines, the imidazo[1,5-a]quinoxalines, and the pyrazolo [1,5-a] quinoxalines. These compounds are analogs of imiquimod, the first member of the imidazoquinolone family, which is used in the topical treatment of genital and anal warts by increasing the activity of the body's immune system (Rudy, 2002; Hengge and Cusini, 2003; Sauder, 2003) . Imiquimod is also efficacious as a topical therapy for certain types of skin cancers (Steinmann et al., 2000; van Egmond et al., 2007; Kang et al., 2009) . Its therapeutic spectrum has been further extended to cutaneous B-cell lymphomas (Spaner et al., 2005) .
The cytotoxic activities of the compounds synthesized by our group have been evaluated in vitro against human cancer cell lines (Moarbess et al., 2008a; Khier et al., 2009 Khier et al., , 2010 . The highest cytotoxic efficacies were obtained with the imidazo[1,2-a]quinoxaline series. On the A375 human melanoma cancer cell line, EAPB0203 (IC 50 1.57 M) had an in vitro activity 110 times higher than that of fotemustine (IC 50 173 M) and 45 times higher than that of imiquimod (IC 50 70 M) (Moarbess et al., 2008a) . In a mouse melanoma model, EAPB0203 was more potent than fotemustine (Moarbess et al., 2008a; Khier et al., 2010) . This compound also displayed interesting cytotoxic activity with micromolar IC 50 values against colon and breast human cancer cell lines (Moarbess et al., 2008a) . The recently synthesized compound, 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0503), showed in vitro cytotoxic activity on an A375 melanoma cancer cell line that was approximately 10 times higher than that of N-methyl-1-(2-phenethyl) imidazo [1,2-a] quinoxalin-4-amine (EAPB0203) (IC 50 150 nM) (Khier et al., 2010) . Thus, EAPB0203 and EAPB0503 have emerged as the most promising drugs. EAPB0203 has also been evaluated in T-cell lymphomas and human T-lymphotropic virus type I (HTLV-I) associated adult T-cell leukemia/lymphoma (Moarbess et al., 2008b) . This compound exhibits significant cytotoxicity in vitro on HTLV-I-infected CD4 ϩ T-cell lines HuT-102, MT-2, and C91-PL as well as on HTLV-1-negative malignant CD4
ϩ T-cell lines CEM, Jurkat, HuT-78, and MOLT-4. We have shown that imidazo[1,2-a]quinoxaline derivatives inhibit cyclic nucleotide phosphodiesterase enzymes 4, resulting in an increased intracellular cAMP level and, consequently, cAMP response element-binding protein phosphorylation (Deleuze-Masquéfa et al., 2004) , and that these compounds activate the p38 mitogen-activated protein kinase pathway and inhibit the phosphatidylinositol 3-kinase pathway (Morjaria et al., 2006) . The mechanism of action of EAPB0203 has been studied in T-cell lymphomas and HTLV-Iassociated adult T-cell leukemia/lymphoma (Moarbess et al., 2008b) . This compound exhibits inhibition of cell proliferation, G 2 /M cell cycle arrest, and induction of apoptosis in HTLV-I-transformed and HTLV-I-negative malignant T cells, whereas normal resting or activated T lymphocytes are resistant. Furthermore, EAPB0203 almost completely inhibited the growth of freshly isolated ATL cells at concentrations of 1 to 10 M. EAPB0203 treatment significantly down-regulated the antiapoptotic proteins c-IAP-1 and Bcl-XL, resulting in a significant loss of mitochondrial membrane potential, cytoplasmic release of cytochrome c, and caspase-dependent apoptosis. In addition, in HTLV-I-transformed cells only, EAPB0203 treatment stabilized p21 and p53 proteins but had no effect on nuclear factor-B activation.
In the present article, we determined the binding of EAPB0203 and EAPB0503 to human plasma proteins and human serum albumin (HSA) solutions in vitro, and we investigated the in vitro metabolism of these two compounds by comparing the metabolite profiles in rat, mouse, dog, and human liver microsomes. Specific chemical inhibitors were used to identify the P450 enzymes that play a role in the metabolism of these compounds. Metabolites were identified using a liquid chromatography (LC)/electrospray ionization (ESI)-mass spectrometry (MS) method. Moreover, results on the distribution, metabolism, and elimination of EAPB0203 and EAPB0503 in rat, one of the principal species used in preclinical studies, are reported.
Materials and Methods
Chemicals. N-methyl-1-(2-phenethyl) imidazo [1,2-a] quinoxalin-4-amine (EAPB0203) (molecular weight 302), 1-(2-phenethyl)imidazo[1,2-a]quinoxalin-4-amine (EAPB0202) (molecular weight 288), 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0503) (molecular weight 304), 1-(3-hydroxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0603) (molecular weight 290), 1-(3-methoxyphenyl)imidazo[1,2-a]quinoxalin-4-amine (EAPB0502) (molecular weight 290), and 1-(3-hydroxyphenyl)imidazo[1,2-a]quinoxalin-4-amine (EAPB0602) (molecular weight 276) (Fig. 1, A and B) were synthesized by the Pharmacochemistry and Biomolecule Laboratory (Montpellier I University, Montpellier, France) . The purity of these standards was evaluated by elemental analysis, LC-MS, and NMR. They were stored at 20°C, protected from light. The physicochemical properties of these molecules are presented in Table 1 . Human plasma was obtained from blood samples collected from healthy volunteers not undergoing drug therapy (Etablissement Français du Sang, Montpellier, France). Crystallized HSA, NADH, NADPH, ketoconazole, quercetin, sulfaphenazole, coumarin, ␣-naphthoflavone, diethyldithiocarbamate, quinidine, and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich (St. Louis, MO). Human, dog, rat, and mouse liver microsomes were purchased from BD Biosciences (Le Pont de Claix, France). All other chemicals and solvents were purchased from commercial suppliers and were of highperformance liquid chromatography grade.
Analytical Methods. EAPB0503, EAPB0203, and their metabolites were quantified in rat plasma using validated LC/ESI-MS methods (Khier et al., , 2010 . The LC-MS analysis was performed using an 1100 quadrupole mass spectrometer (Agilent Technologies, Les Ulis, France) coupled to a Hewlett Packard LC system equipped with an autosampler set at 4°C. In brief, the sample pretreatment procedure involved solid-phase extraction of plasma using an Oasis HLB cartridge after protein precipitation with 10 ml/l trifluoroacetic acid. The internal standard used was of the same chemical series.
Chromatography was performed at 20°C on a C8 Zorbax eclipse XDB column with a mobile phase consisting of acetonitrile and formate buffer (pH 3) gradient elution (flow rate, 0.8 ml/min). LC-MS data were acquired in single ion monitoring mode at m/z values corresponding to the protonated molecules, [M ϩ H] ϩ . The drug/internal standard peak area ratios were linked via quadratic relationships to plasma concentrations. The methods are precise (precision, Յ14%) and accurate (recovery, 92-113%). Mean extraction efficiencies Ͼ72% for each analyte were obtained. No significant matrix effects occurred. Dilution had no influence on the performance of the method. The lower limit of quantitation (LLOQ) was 5 g/l (i.e., ϳ0.017 M) for each of the analytes.
Animal samples were processed with a standard curve. Quality control samples were included in each analytical sequence to verify the stability of study samples during storage and accuracy and precision of analysis.
Identified metabolites and their parent drugs were quantified in microsomal incubates using the LC-MS conditions described above. Samples were processed with an eight-point standard curve prepared in a mixture of buffer (containing all the components for microsomal incubation, except NADH) and acetonitrile. Calibrators were prepared by spiking appropriate amounts of each compound (EAPB0203 and EAPB0202 or EAPB0503, EAPB0502, EAPB0603, and EAPB0602) to the buffer-acetonitrile mixture to obtain final concentrations in the range of 0.05 to 10 M. In the absence of analytical standards, the relative amount of each hydroxylated metabolite was calculated using the formula, [(C met (micromolar concentration) Ϫ C demet (micromolar concentration))ϫ (peak area of one hydroxylated metabolite/peak areas of all hydroxylated metabolites)] ϫ 100/Cmet (micromolar concentration), where C met is the hydroxylated plus demethylated metabolite concentration calculated by subtracting the unmetabolized concentration after microsomal incubation (micromolar concentration) from the initial concentration before microsomal incubation (i.e., 10 M in the buffer-acetonitrile mixture) and C demet is the sum of all demethylated metabolites quantified in the incubation medium.
In an attempt to identify hydroxylated derivatives, a 6400 series triple quadrupole LC-MS/MS system (Agilent Technologies) was used. Chromatographic conditions were similar to those described above. The mass selective detector was operated in scan mode for the qualitative analyses of microsomal incubates (m/z from 100 to 320). Nebulizer pressure was 35 psi, and the drying gas (nitrogen) was delivered at 12 l/min. Capillary and nozzle voltages were 3000 and 1500 V, respectively. The fragmentor (collision-induced dissociation cell) was set at 35 V.
Human Plasma Protein Binding. Plasma protein binding of EAPB0203 and EAPB0503 was determined by ultracentrifugation, because preliminary studies showed that these compounds were both subject to unacceptable levels The lack of proteins in the supernatant was assessed using a bicinchoninic acid protein assay kit (Sigma-Aldrich). The time necessary for achievement of equilibrium was determined in a preliminary study at concentrations of 50, 100, and 1000 g/l (i.e., ϳ0.16, 0.33, and 3.3 M). For this study, multiple spiked plasma samples (10 ml each) in polypropylene tubes were placed in an incubator at 37°C for 0.5 to 3 h. At selected time intervals, one tube was removed, and an 8-ml aliquot of plasma was introduced in a polycarbonate tube, which was then centrifuged in a precooled rotor at 100,000g for 14 h at ϩ4°C using an Optima LE70 ultracentrifuge (Beckman Coulter, Fullerton, CA). The free fraction in the supernatant taken from halfway between the supernatant surface and the pellet was analyzed. The remaining 2 ml were used to quantify the total drug concentration. With the use of optimized conditions (i.e., 2 h at 37°C), the percentage of bound drugs in plasma was determined from plasma spiked samples at concentrations of 62.5, 100, 500, 1000, and 2000 g/l (i.e., ϳ0.21-6.6 M). Samples were placed at 37°C for 2 h and then were centrifuged according to the same procedure as described above.
In a second phase of this study, EAPB0203 and EAPB0503 binding by HSA at approximately physiologic concentrations of this protein (40 g/l in pH 7.4 phosphate buffer) was studied. The percentage of bound drug was determined at concentrations of 62.5, 100, 250, 500, and 1000 g/l (i.e., ϳ0.21-3.3 M). Thereafter, the association (K a ) and dissociation (K d ϭ 1/K a ) constants were determined. For this, each compound, at concentrations of 62.5, 250, and 1000 dmd.aspetjournals.org g/l, was added to albumin solutions at concentrations ranging from 0.25 to 40 g/l (0.25, 0.5, 1, 2.5, 5, 10, and 40 g/l). The following Scatchard equation (Scatchard, 1949) was used:
where n is the number of binding sites per albumin molecule, r is the number of moles of bound drug per mole of protein and [D f ] is the molar concentration of free drug. By plotting r/[D f ] against r, the association constant is calculated.
The nonspecific binding of EAPB0203 and EAPB0503 to human liver microsomes [f B(microsomes) ] was also evaluated. Binding experiments were conducted at 37°C to mimic conditions used in in vitro microsomal metabolism studies but were conducted in the absence of NADH so that metabolism of the compounds would not occur. The methodology used was similar to that described above for HSA. All determinations were performed in triplicate.
In Vitro Metabolism Assays with Liver Microsomes. These studies were conducted in accordance with the European Medicines Agency's guidance document on the conduct of in vitro metabolism studies (Guideline on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals, 2009, http://www.ema.europa.eu/pdfs/vet/vich/46310409en.pdf) and the principles promulgated by Jia and Liu (2007) and Huang et al. (2008) . All determinations were performed in replicates (n ϭ 3-4).
General protocol for microsomal incubations. Control incubations were performed to ensure that metabolite formation required microsomal enzymes and cofactor. Pilot experiments were performed to obtain optimum metabolic activity. The cofactor (NADH or NADPH), the pH (6.3 or 7.4), and the time of incubation were optimized. Incubations were performed under aerobic conditions at 37°C in a shaking incubator. The best conditions were obtained when the substrates, dissolved in DMSO and then diluted in phosphate buffer (pH 6.3, final DMSO concentration Ͻ1%, v/v) containing 1% bovine serum albumin, were incubated 4 h with pooled liver microsomes (1 g of protein/l) in 0.25-ml incubation mixtures containing potassium phosphate buffer (pH 6.3). In the incubation medium, concentrations of EAPB0203 and EAPB0503 were 20 M. Moreover, using these optimal conditions, experiments ensured that metabolite formation was linear with time (15-240 min) and protein concentration (from 0.2 to 4.8 g/l). Zero time, zero substrate, zero protein, and zero cofactor served as controls. After an initial preincubation of 15 min with substrate, reactions were initiated by the addition of NADH (10 mM). The reaction was terminated by addition of 250 l of ice-cold acetonitrile containing 1% formic acid and the internal standard. Precipitated proteins were removed by centrifugation (14,000g for 20 min at 4°C), and the supernatant fractions were analyzed by LC-MS.
Enzyme kinetics in human liver microsomes and estimation of intrinsic clearance. For both EAPB0203 and EAPB0503, intrinsic clearances (CL int, in vitro ) were calculated from substrate disappearance rate in presence of human liver microsomes (1 g/l). The substrate disappearance with time (0, 5, 10, 30, 60, 90, 120, 180 , and 240 min) followed a first-order reaction; thus, the unchanged drug profile as a function of time was described as C t ϭ C 0 e Ϫkext , where C 0 is the initial concentration of the drug and ke is the disappearance rate constant. CL int, in vitro was calculated from the equation, k e /D cell , where D cell is the cell density (grams per milliliter) (Naritomi et al., 2003) . With the use of scaling factors published by Carlile et al. (1997) and Obach (1999) , 45 mg of microsomal protein/g of liver and 20 g of liver/kg b.wt., the in vivo intrinsic clearance (CL int, in vivo ) was calculated.
For EAPB0203, CL int, in vitro was also calculated from the Michaelis-Menten parameters, by incubating increasing concentrations of EAPB0203 (0.3-50 M) in human microsomal preparations according to the protocol described above. CL int, in vitro was calculated as the ratio of V max over K m . (Houston and Kenworthy, 2000) .
From the CL int, in vivo values, the human hepatic plasma clearance (CL Hp ) was calculated using the well stirred model as follows (Yang et al., 2007) :
where f u is the unbound fraction in plasma, C blood is the drug concentration in the blood, C plasma is the plasma drug concentration, f u(microsomes) is the unbound fraction in the microsomal reaction mixture, and Q H is the hepatic blood flow in human [21 ml/(min ⅐ kg)]. The blood/plasma concentration ratio was evaluated in vitro after incubation of 1-ml aliquots of blood for 1 h at 37°C with the analytes (2 and 20 M for each compound).
Inhibition studies. The choice of inhibitors and their concentrations was based on literature data (Reidy et al., 1989; Halpert et al., 1994; Rodrigues, 1994; Baldwin et al., 1995; Bourrié et al., 1996) . EAPB0203 and EAPB0503 were incubated in human, dog, rat, and mouse liver microsomes in the presence and absence of the following selective inhibitors: ketoconazole (CYP3A) (Eagling et al., 1998) ; quercetin (CYP2C8) (Rahman et al., 1994) ; sulfaphenazole (CYP2C9) (Newton et al., 1995) ; coumarin (CYP2A6) (Pearce et al., 1992) ; ␣-naphthoflavone (CYP1A1/2) (Rendic and Di Carlo, 1997) ; diethyldithiocarbamate (CYP2E1 and CYP2A) (Rendic and Di Carlo, 1997) , and quinidine (CYP2D6) (Newton et al., 1995) . ␣-Naphthoflavone was also an activator of CYP3A activity. Two concentrations of each inhibitor were used; inhibitor concentrations are shown in Fig. 2 for EAPB0203 and in Fig. 3 for EAPB0503; concentrations of ␣-naphthoflavone were 100 and 500 M. Stock solutions of inhibitors were prepared in deionized water (diethyldithiocarbamate), methanol (␣-naphthoflavone, ketoconazole, sulfaphenazole, and coumarin), DMSO (quinidine), or 0.1 M sodium hydroxide (quercetin). They were extemporaneously diluted to the appropriate concentrations with phosphate buffer (pH 6.3). All inhibitors and substrates were preincubated before the addition of NADH, as described above.
Pharmacokinetic Studies. This research adhered to the Principles of Laboratory Animal Care (National Institutes of Health publication 85-23, revised 1985) . The animal studies were approved by the local animal use committee.
Animals. Sprague-Dawley male rats from Charles River (L'Arbresle, France) were housed in standard wire-bottom cages (maximum of six rats per cage) and allowed free access to a standard rodent diet (UAR sterile food; Usine d'Alimentation Rationnelle, Villemoisson, Epinay sur Orge, France) and water. They were kept under conditions of constant temperature (21-25°C) and relative humidity of approximately 40 to 65% with a standard light/dark cycle. Body weights at the time of dosing were 200 to 250 g. All animals underwent a period of 1 week of observation and acclimatization before treatment. Rats were fasted overnight (12 h) before drug administration and then weighed.
Dosing. Rats were randomly distributed in four experiment groups. In the first two groups, rats received single 5 mg/kg i.v. and i.p. doses of EAPB0503; in the third and fourth groups, rats received single 2.5 mg/kg i.v. and i.p. doses 
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Blood sampling. After single dose administration, blood (one sample per rat, three animals per time point) was obtained at 5, 10, and 30 min and at 1, 2, 4, 8, 12, 24, and 36 h postdose. Samples were collected after sacrifice of the animals by section of the carotid artery. Two minutes before sampling, animals were anesthetized with sevofluran. Blood samples were collected in heparinized polypropylene tubes (0.1 ml of lithium heparinate/tube), immediately placed on ice, and then centrifuged (4000g) at 4°C for 10 min. The plasma was separated and then immediately stored at Ϫ80°C until assay.
Pharmacokinetic data processing. After single administration, pharmacokinetic parameters were calculated by noncompartmental analysis from the average concentration values at each time point using the Pk-fit software (Farenc et al., 2000) . When the concentrations were below the quantitation level, mean values were obtained from several values at or above the LLOQ with the other values taken as zero. The area under the mean plasma drug concentration versus time curve extrapolated to infinity (AUC) was estimated using the log/linear trapezoidal method. The total plasma clearance (CL) and steady-state volume of distribution (V ss ) of the parent drug were calculated from the relationships, CL ϭ dose/AUC and V ss ϭ CL ϫ (AUMC/AUC), respectively, where AUMC is the area under the first moment of the concentration-time curve. The terminal half-life (t 1/2 ) was calculated as ln2/k, where k is the rate constant determined from the slope of the log linear part curves. The absolute bioavailability (F) was calculated from the AUC values obtained for both the parent drug and its active metabolite(s) exhibiting similar in vitro cytotoxicity as the parent compound (i.e., EAPB0202 for EAPB0203 and EAPB0603 and EAPB0502 for EAPB0503) as F ϭ (AUC unchanged compoundϩactive metabolite(s) ) i.p./ (AUC unchanged compoundϩactive metabolite(s) ) i.v.
Results
Plasma Protein Binding. EAPB0203 and EAPB0503 bound strongly to plasma proteins and HSA (approximately 98 -99.5%). For both compounds, only a small fraction was present in free form. For drug concentrations between 62.5 and 1000 g/l, the percentage of EAPB0203 and EAPB0503 bound at 40 g/l HSA is presented in Table 2 . Although a few differences were observed, the percentage of bound drug appeared to increase with the drug concentration over the range of concentrations studied. Similar results were obtained with human plasma (data not shown). However, using the Kruskal-Wallis test, the difference was not statistically significant ( p ϭ 0.0769 for EAPB0203 and p ϭ 0.13 for EAPB0503). The extent of binding of EAPB0203 and EAPB0503 with different concentrations of HSA is shown in Supplemental Fig. 1 . The binding was reduced to 65 to 70% at a very low concentration of albumin (0.25 g/l). For EAPB0203 and EAPB0503, the Scatchard plots showed patterns in which the plots yielded upwardly convex hyperbolic curves (Fig. 4) . With the Hill equation, the Hill coefficients (n), calculated from the natural logarithm of r/(1 Ϫ r) versus the logarithm of free drug concentration, were n ϭ 1.42 (95% confidence interval 1.26 -1.57) for EAPB0203 and n ϭ 1.32 (95% confidence interval 1.14 -1.50) for EAPB0503. These values, greater than 1, could indicate positive cooperativity of binding. The dissociation constants, K D , were 0.18 ϫ 10 Ϫ6 M for EAPB0203 and 0.46 ϫ 10 Ϫ6 M for EAPB0503. The corresponding association constants were 5.55 ϫ 10 6 M and 2.18 ϫ 10 6 M, respectively. Estimated K D values were similar to the lowest concentrations tested (0.21 M), but in the experimental conditions used, we could not evaluate lower drug concentrations because we were limited by the LLOQ of the free fraction. Thus, the estimation of K D was repeated from lower drug concentrations (33, 50, 100, 165, 200 , and 210 nM) but using a single albumin concentration of 0.25 g/l. Estimated K D values were of the same order of magnitude: 0.26 ϫ 10 Ϫ6 M for EAPB0203 and 0.23 ϫ 10 Ϫ6 M for EAPB0503. In Vitro Metabolism Studies. Metabolic identification. Quantitatively, rat and dog metabolized the compounds with a higher rate than mouse and human (Supplemental Fig. 2 ). When EAPB0203 was incubated with rat, dog, mouse, and human liver microsomes in the presence of NADH for 4 h, 55, 68, 27.5, and 34% of the drug were metabolized, respectively. The LC-MS analysis of liver microsomal incubates allowed identification of eight metabolites related to an oxidative process (hydroxylation and N-demethylation) that did not appear when NADH was omitted from the mixture. These compounds were more polar than EAPB0203 (retention time 6.5 min) and eluted at 3.6 min (M1), 4.0 min (M2), 4.1 min (M3), 4.2 min (M4), 4.5 min (M5), 4.5 min (M6), 4.8 min (M7), and 5.8 min (M8) (Fig. 5) . The first metabolism route in all species studied consisted of an oxidative 
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N-demethylation of EAPB0203 yielding EAPB0202 (M8, protonated molecule at m/z 289). The structure of EAPB0202 was proposed based on the LC-MS spectra and on the basis of coelution with a reference compound. Microsomes from human were the most effective Ndemethylating system (39% of total metabolite levels), followed by those of mouse (22%) ( Table 3) . A second pathway resulted in the formation of four hydroxylated derivatives of EAPB0203 (M2, M4, M6, and M7; protonated molecules at m/z 319). They were detected in all the species except the dog. Human and mouse microsomes predominantly formed M2 and M7, whereas rat microsomes favored the production of M2 and M6 and dog microsomes the production of M2 (Supplemental Fig. 2 ). Other hydroxylated metabolites (M1, M3, and M5) showed the protonated molecules at m/z 305. These metabolites could correspond to the hydroxylated derivatives of EAPB0202. Most of them were formed at low levels. Table 3 summarizes the relative abundance of the metabolites identified in liver microsomes from animal species and human. In an attempt to identify hydroxylated derivatives, microsomal incubates were analyzed by LC-MS/MS. On the basis of fragmentation patterns deduced from the spectra obtained, two hydroxyl groups dmd.aspetjournals.org could be positioned on the imidazoquinoxaline cycle (M6 and M7) and the others (M2 and M4) on the phenyl cycle of the phenethyl group. M5 should be the demethylated compound of M7, M1 that of M2, and M3 that of M6. However, in the absence of standards, the precise oxidation position could not be elucidated further in view of the mass spectrometry data available. For the exact identification of these unidentified metabolites, more experimental work should be performed. The metabolic scheme is presented in Fig. 1A .
Incubations of pooled rat, dog, mouse, and human liver microsomes with EAPB0503 (4 h at 37°C in the presence of NADH as a cofactor) were analyzed by LC-MS; 50, 68, 26, and 39% of the drug have been transformed, respectively (Supplemental Fig. 2) . In a typical HPLC separation, EAPB0503 eluted at 6.2 min. Seven more polar EAPB0503 metabolites were separated from the extracted mass chromatograms. They were named accordingly: MЈ1 [retention time (Rt) 3.0 min], MЈ2 (Rt 3.2 min), MЈ3 (Rt 3.5 min), MЈ4 (Rt 3.7 min), MЈ5 (Rt 4.0 min), MЈ6 (Rt 4.1 min), and MЈ7 (Rt 5.3 min) (Fig. 6) . The structures of MЈ2 (EAPB0602, protonated molecule at m/z 277), MЈ5 (EAPB0603, protonated molecule at m/z 291), and MЈ7 (EAPB0502, protonated molecule at m/z 291) were identified based on LC-MS spectra and on the basis of coelution with available standards. At 20 M substrate concentrations, four to seven metabolites were formed by liver microsomes, depending on the species (Supplemental Fig. 2) . EAPB0603 was predominant in human and rat microsomes (39 and 33% of the total metabolite levels, respectively). In contrast, in microsomes from dog and mouse, EAPB0603 is formed to a much lesser extent (Ͻ3 and 8% of total EAPB0503 disappearance, respectively), and the N-demethylated EAPB0502 is the predominant metabolite (it 
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at ASPET Journals on June 23, 2017 dmd.aspetjournals.org Downloaded from accounts for 56 and 27% of total metabolism, respectively). Products eluting with retention times of 3.7 and 4.1 min (MЈ4 and MЈ6) showed the protonated molecule at m/z 321, indicating the molecular mass of hydroxylated derivatives of EAPB0503. Metabolite MЈ4 was detected in all species (from 19% of the total metabolite levels in human and dog to 39% in rat). Metabolite MЈ6 was not detected in human and rat microsomes, whereas it was produced at a high level in microsomes from mouse. MЈ1 and MЈ3 showed the protonated molecule at m/z 307, indicating the molecular mass of demethylated derivatives of MЈ4 and MЈ6, respectively. Metabolite MЈ1 was only detected in dog microsomes. Metabolite MЈ3 was not detected in human and rat and remained very low in dog microsomes. Table 3 reports the relative abundance of the identified metabolites. Based on fragmentation patterns deduced from the spectra obtained by LC-MS/MS, one hydroxyl group should be positioned on the imidazoquinoxaline cycle (MЈ4) and the other on the phenyl group linked to the imidazole cycle (MЈ6). MЈ1 should be the demethylated compound of MЈ4 and MЈ3 that of MЈ6. However, as reported for EAPB0203, the precise oxidation position was not elucidated. Biotransformations by cytochrome P450-mediated EAPB0503 metabolism are presented in Fig. 1B .
In vitro intrinsic clearance. Supplemental Fig. 3 illustrates the time courses of EAPB0203 and the formation of the main metabolites in human microsomal incubation. Mean intrinsic metabolic clearances (CL int, in vitro ) calculated from substrate disappearance rates were 2.37 Ϯ 0.05 ml/(min ⅐ g) protein for EAPB0203 and 2.70 Ϯ 0.038 ml/(min ⅐ g) protein for EAPB0503. For EAPB0203, similar intrinsic clearance was estimated using the Michaelis-Menten parameters. K m and V max values were 20 M and 54.8 pmol/(min ⅐ mg) protein, respectively, yielding a CL int, in vitro of 2.74 ml/(min ⅐ g) protein. The apparent K m value of 20 M indicates that enzymes metabolizing EAPB0203 into EAPB0202 have a modest affinity for the substrate. According to the classification for categorizing compounds (Nassar et al., 2009) , CL int, in vitro could be considered as low to intermediary values. Scaling-up of the CL int, in vitro values to reflect intrinsic clearances on a per kilogram body weight basis for human (CL int, in vivo ) yielded mean values of 2.13 ml/(min ⅐ kg) for EAPB0203 and 2.43 ml/(min ⅐ kg) for EAPB0503. The nonspecific binding of EAPB0203 and EAPB0503 to human microsomes [f B(microsomes) ] calculated from 1.0 g of protein/l and drug concentrations at 20 M was 95.5%. Thus, unbound CL int, in vivo values, calculated from CL int, in vivo and f u(microsomes) , were 47.1 ml/(min ⅐ kg) for EAPB0203 and 54.0 ml/(min ⅐ kg) for EAPB0503. Predictions for the human hepatic plasma clearances with the "well stirred" model incorporating f u , f u(microsomes) , and a factor C blood /C plasma of 0.6 for both EAPB0203 and EAPB0503 gave the following results: 0.92 ml/(min ⅐ kg) for EAPB0203 and 0.74 ml/(min ⅐ kg) for EAPB0503.
Inhibition study. The relative contributions of CYP1A1/2, CYP2A, CYP3A, CYP2C8/9, CYP2D6, and CYP2E1 to EAPB0203 and EAPB0503 N-and O-demethylation in liver microsomes were investigated. Studies to identify the P450 isoform(s) involved in EAPB0203 and EAPB0503 hydroxylations were also undertaken. As shown in Fig. 2 , for all species, CYP3A was found to play the major role in EAPB0203 N-demethylation. At high and low concentrations, ketoconazole decreased EAPB202 formation by approximately 50% in human liver microsomes and by approximately 60% in mouse liver microsomes. In dog and rat liver microsomes, coincubation of EAPB0203 with a high ketoconazole concentration resulted in approximately 40% (dog) and 60% (rat) inhibition of EAPB202 formation; less than 20% were inhibited at low concentration. CYP2A6 and CYP2C9 in human, CYP2E1 in dog and mouse, and CYP2C9 at a high concentration of sulfaphenazole in rat also contributed significantly to EAPB0202 formation (Fig. 2) . CYP1A1/2 and CYP3A predominantly generated hydroxylated metabolites of EAPB0203. At high and low concentrations, ␣-naphthoflavone inhibited formation of all hydroxylated metabolites of EAPB0203 in mouse hepatic microsomes, with similar 46% inhibition. This compound decreased formation of M2 and M7 by 40% in dog microsomes; but it had a much weaker inhibitory effect in human and rat microsomes (approximately 6 -10%). At the two concentrations studied, ␣-naphthoflavone also inhibited completely the formation of M4 in rat microsomes and inhibited the formation of this metabolite by 49% in human microsomes. Except in mouse, no effect of this compound was observable on M6 formation. In all species, we observed a stimulatory effect of ␣-naphthoflavone on the formation of EAPB0202 (5-fold in human and mouse and 3-fold in rat and dog). The inhibitor of CYP3A, ketoconazole, had also an important inhibitory effect on the formation of M2 (48% in human and 12% in mouse), M6 (52% in human, 33% in dog, and 10% in rat and mouse microsomes), and M7 (95% in human, 34% in rat, 64% in mouse, and 11% in dog microsomes). P450s of CYP2A and CYP2E1 subfamilies also participated in formation of hydroxylated metabolites of EAPB203 (M4 in human, M6 in rat and dog, and M7 in dog microsomes) but only to a lesser extent (18 -23%).
As presented in Fig. 3 , in all species, ketoconazole inhibited Ndemethylation of EAPB0503 by approximately 40 to 65%, followed by coumarin (ϳ20%) and sulfaphenazole (ϳ10%) in human, diethyldithiocarbamate (ϳ18%) in dog, and quercetin (ϳ18%) in rat. Ketoconazole also inhibited O-demethylation of EAPB0503 by approximately 20 to 45% in human, rat, and dog microsomes. The contribution of CYP3A to the formation of EAPB0603 was less important in mouse microsomes (ϳ5%). Other isoforms were implicated in the O-demethylation of EAPB0503: CYP2A, CYP2C8, CYP2C9, and CYP2E1 in human and CYP2C8 and CYP2E1 in rat. Except for quercetin and diethyldithiocarbamate in rat, there was little influence of inhibitor concentrations on the percentage of inhibition. In microsomes of all species, ␣-naphthoflavone inhibited formation of MЈ4 (40 -50% in human, rat, and dog and 90% in mouse), and this compound inhibited completely the formation of MЈ6 in mouse and dog microsomes. In all species, we observed a stimulatory effect of ␣-naphthoflavone on the formation of EAPB0502 (1.3-2-fold). CYP3A was also involved in the formation of MЈ4 in rat microsomes (inhibition by ketoconazole, 26%); the contribution of this isoform was less important in human and mouse microsomes (inhibition by ketoconazole of approximately 10%). CYP2C9 also contributed significantly to MЈ4 and MЈ6 formation in rat microsomes (inhibition by sulfaphenazole of approximately 40%). Pharmacokinetics. Some results presented here have been published previously in our earlier works (Khier et al., , 2010 . Here, we summarize all available data on the pharmacokinetics of the two lead compounds. In vivo, EAPB0203 was metabolized to give EAPB0202 and four hydroxylated metabolites, M1, M2, M3, and M6. Biotransformation of EAPB0503 involved two demethylation steps leading to the formation of EAPB0603, EAPB0502, and EAPB0602 and one hydroxylation step leading to the formation of MЈ4. EAPB0603 was the main metabolite. Unfortunately, in the absence of standards, the hydroxylated metabolites identified in vivo have not been quantified.
After both intravenous and intraperitoneal administration, the declines in the EAPB0203 and EAPB0202 plasma concentrations take place in two phases: an initial phase in which the rate of decline is rapid followed by a prolonged terminal phase (Khier et al., 2010) . Plasma concentrations versus time curves after EAPB0503 administrations are presented in Fig. 7 . EAPB0503 and EAPB0603 exhibited a two-phase decline in plasma concentration, whereas for EAPB0502 and EAPB0602, a monoexponential decline was observed. Basic pharmacokinetic parameters for EAPB0203 and EAPB0503 and their metabolites are presented in Table 4 . The pharmacokinetic parameters showed a 72% 
dmd.aspetjournals.org greater steady-state volume of distribution (4.3 versus 2.5 l/kg) for EAPB0203 relative to that for EAPB0503. However, the terminal half-lives of the two parent compounds were similar, ϳ2 h. After intraperitoneal administration, systemic bioavailability was 22.7% for EAPB0203 and 35% for EAPB0503. The metabolic ratios, AUC metabolite/AUC parent drug, were higher after intraperitoneal administration than after intravenous administration, suggesting a hepatic first-pass effect after intraperitoneal administration. The terminal halflives of EAPB0202, EAPB0502, and EAPB0602 were similar to those of the parent drugs, whereas that of EAPB0603 was delayed compared with the elimination of EAPB0503.
Discussion
From the many structurally related compounds, analogs of imiquimod, that have been synthesized and tested to date, two compounds, EAPB0203 and EAPB0503, have emerged as the most promising based on their in vitro and in vivo activities on melanoma and T-lymphomas (Moarbess et al., 2008a,b; Khier et al., 2010) . Some data on the mechanism of action of these two compounds have been published (Morjaria et al., 2006; Moarbess et al., 2008b) . However, the specific cellular targets of these two compounds remain to be identified.
Drug-albumin interaction is a major challenge in distribution-metabolism-elimination prediction. The results from this study demonstrate that, over the concentration range 62.5 to 2000 g/l, EAPB0203 and EAPB0503 are extensively bound to human plasma proteins and HSA at a physiologic concentration of this protein (ϳ98 -99.5%). Thus, HSA could act as a carrier of these compounds in human plasma. These values seem compatible with the ionization constants and lipophilicity of EAPB0203 and EAPB0503 (Table 1) , showing that these drugs are acting like weak bases (Ermondi et al., 2004) . The in vitro study also demonstrated an unusual concentration dependence of EAPB0203 and EAPB0503 binding in human plasma and HSA. We can see that the binding of EAPB0203 and EAPB0503 in HSA increased slightly with increasing drug concentration ( Table 2) . Similar results were obtained in human plasma. However, the difference was not statistically significant. One possible explanation for this behavior is that the concentration of unbound drugs is limited by their low solubility, whereas the capacity of proteins to bind EAPB0203 and EAPB0503 is much larger. However, such variations did not exceed 2% and are within the range of precision authorized in bioanalysis. The binding status of the drugs and HSA was assessed in vitro by the Scatchard method. Results obtained could suggest the presence of positive cooperativity in which affinity between the unbound drug and the sites to which the drug is bound increases as the drug binds to the binding sites. These results could also be explained by the presence of albumin aggregates. Indeed, Lin et al. (2000) have reported that the lyophilized protein exhibits a higher level of aggregation upon dissolution. Calculated K D values were similar for the two compounds: 0.26 ϫ 10 Ϫ6 M for EAPB0203 and 0.23 ϫ 10 Ϫ6 M for EAPB0503. In this study, hepatic cytochrome P450-dependent EAPB0203 and EAPB0503 metabolism has been extensively compared in microsomes representing four mammalian species including human, and qualitative and quantitative interspecies differences were observed. Quantitatively, rat and dog metabolized the compounds with a higher rate than mouse and human. A proposed scheme for the metabolism of EAPB0203 is shown in Fig. 1A . EAPB0203 was metabolized via two main metabolic pathways: first, N-demethylation leading to the formation of EAPB0202 and, second, arising through a series of hydroxylations. Human microsomes have a greater capacity than rat, dog, and mouse microsomes to N-demethylate EAPB0203. The cytotoxicity of EAPB0202 against the A375 melanoma cancer cell line was similar to that of the parent compound (Moarbess et al., 2008a) . Thus, this compound had a significant role in the antitumoral activity of EAPB0203. The second pathway appeared to be the most important in all species studied, forming one to two major hydroxylated metabolites of EAPB0203 (Table 3) . Hydroxylated metabolites of EAPB0202 were detected to a lesser extent. EAPB0503 was metabolized via three main metabolic pathways as shown in Fig. 1B . Of the seven metabolites detected, three of them, EAPB0603, EAPB0502, and EAPB0602, were identified. In human, rat, and dog microsomes, the main metabolite routes (accounting for at least 60% of total EAPB0503 disappearance) consisted of N-and O-demethylation, leading to the formation of EAPB0603, EAPB0502, and EAPB0602. EAPB0603 (formed by O-demethylation) and EAPB0502 (formed by N-demethylation) were as active as EAPB0503 on the A375 human cancer cell line, whereas EAPB0602 was found to be less effective (52-fold according to its IC 50 value). Thus, EAPB0603 and EAPB0502 are significantly involved in the global antimitotic activity of EAPB0503. EAPB0603 was one of the main metabolites in human and rat; EAPB0502 was one of the main metabolite in dog and mouse. Another pathway resulted in the formation of two EAPB0503 hydroxylated derivatives (MЈ4 and MЈ6) and their corresponding demethylated compounds. MЈ4 was detected in all hepatic microsomal incubates, whereas MЈ6 was not detected in human and rat microsomes. The highest percentage of hydroxylated compounds (64%) was observed in mouse microsomes. Only rat microsomes generated the pattern of EAPB0503 metabolites reproducing that formed by human microsomes. Unfortunately, for the hydroxylated metabolites, the precise oxidation position could not be elucidated further in view of the mass spectrometry data available. The present study suggested that the CYP3A isoform was the predominant enzyme responsible for N-and O-demethylation of EAPB0203 and EAPB0503 in human, rat, dog, and mouse microsomes. Inhibition results indicated that other P450 isoforms were involved in the demethylation: CYP2A, CYP2C9, CYP2E1, and CYP2C8 in human; CYP2C9 and CYP2C8 in rat; and CYP2E1 in dog and mouse. CYP1A1/2 and CYP3A were found to be the principal enzymes generating hydroxylated metabolites.
The implementation of assays regarding metabolic behavior to enable reliable prediction of hepatic clearance in human of new chemical compounds is a major component of lead optimization in drug discovery. Human liver microsomes are the most useful high-throughput tool for identifying high-clearance compounds. Thus, in this study, intrinsic clearance was calculated from the substrate depletion approach and the nonspecific binding of the drugs to human microsomes was determined by ultracentrifugation. Indeed, for in vitro-in vivo scaling, correction with f u(microsomes) in the reaction mixture has been reported to be important (Obach, 1999) . EAPB0203 and EAPB0503 were metabolized in human liver microsomes with in vitro unbound intrinsic clearances of 52.7 and 60.0 ml/(min ⅐ g) protein, respectively. The extrapolation of in vivo metabolic drug clearance from in vitro data was performed using the most commonly used scaling factors (Carlile et al., 1997; Obach, 1999) . By doing this, in vivo intrinsic clearances for unbound EAPB0203 and EAPB0503 were 47.1 and 54.0 ml/(min ⅐ kg), respectively. From these values, in combination with those from the well stirred model, the hepatic plasma clearances were estimated to be 0.92 ml/(min ⅐ kg) for EAPB0203 and 0.74 ml/(min ⅐ kg) for EAPB0503. Most of the metabolites identified in vitro in rat hepatic microsomes were also found in vivo. These results confirm in vitro studies. In the absence of standards, hydroxylated metabolites have not been quantified in rat plasma. Except for EAPB0603, the terminal half-lives of the metabolites were similar to those of the parent drugs. In this case, the real metabolite half-life could not be estimated. EAPB0603 was excreted much more slowly than the parent compound. The delayed elimination of this metabolite may involve a rate driven by the elimination process. Total systemic clearances of EAPB0203 and EAPB0503 [3.2 and 2.2 l/(h ⅐ kg), respectively] were notably less than the typical cardiac plasma output in rat [9.6 l/(h ⅐ kg)] (Davies and Morris, 1993) . Plasma clearance of EAPB0503 was comparable with the average hepatic and renal plasma flows in rat [1.8 l/(h ⅐ kg)] (Davies and Morris, 1993) . The steady-state volumes of distribution of 4.3 l/kg for EAPB0203 and 2.5 l/kg for EAPB0503 were well in excess of the total body water volume in rat (0.67 l/kg) (Davies and Morris, 1993) , suggesting that tissue binding was extensive and greater than plasma binding. The differences in the volume of distribution between the two drugs were in agreement with the higher lipophilicity of EAPB0203 (logP, 4.91) compared with that of EAPB0503 (logP, 3.45). After intraperitoneal administration a significant hepatic first-pass effect was observed. The absolute bioavailability of the two compounds did not exceed 40%. These results could be due to low intraperitoneal absorption, large first-pass metabolism [formation of inactive or poorly active metabolites (as EAPB0602)], or a combination of both.
In conclusion, this study generated substantial information about the distribution, metabolism, and elimination of two compounds, EAPB0203 and EAPB0503, belonging to a new series of promising anticancer drugs, the imidazo[1,2-a]quinoxalines.
